During 2023, Icon invested over $85 million in new cancer centres and welcomed 15% growth across our global doctor network, doubling down on our capacity to deliver more care.
Icon Group celebrates a year of growth and pioneering advancements in healthcare
As we farewell 2023 and welcome a new year, we reflect on the many achievements Icon Group has made together.
We opened new state-of-the-art centres and services, introduced more of the latest cancer treatments and technologies, invested in our research, compounding and pharmacy capabilities, and signed strategic partnership to enable growth in new markets in the United Kingdom and Malaysia.
Throughout the year, Icon delivered over three million patient interactions across 53 cancer centres, five compounding facilities and the management of over 70 pharmacies. Here’s some of the standout that demonstrated our contribution to reducing the global cancer burden:
New geographies and more care
- Australia growth
We opened two new cancer centres in Australia at Auchenflower in Brisbane and Mildura in regional Victoria. In the six months since opening, the Mildura centre has made a significant impact to cancer patients in the region having already completed more than 3,200 individual radiation treatment sessions with over 130 patients competing their treatment.Our established national network also saw the continued introduction of new technologies and services as well as celebrating significant service milestones including Icon Cancer Centre Townsville’s 10th birthday. Construction also continued to progress on our new centre at Noosa, which will transform cancer care in Queensland’s sunshine coast. - ASEAN expansion
Icon continued to see sustainable growth in the ASEAN region with the opening of the flagship Icon Cancer Centre at Mt Alvernia Hospital. This $25 million facility is the first of its kind in Singapore delivering all aspects of cancer care under one roof.In September Icon joined with Sunsuria Healthcare in a joint venture partnership which provide world-leading cancer care services and help narrow the gap in access to cancer care in Malaysia. The first centre in this partnership will be at Penang’s Island Hospital, slated to open in January 2024. This marked a significant milestone in Icon’s continued maturity and expertise in region. - Entry into United Kingdom
2023 also saw the announcement of a strategic partnership between Icon and Nuffield Health to deliver oncology services in the United Kingdom. This was shortly followed by Icon’s debut at London Global Cancer Week with team members sharing Icon’s clinical care expertise and innovative solutions to addressing the global cancer workforce shortages.
Operational excellence
- Quality compounding services
Icon’s leading compounding division, Slade Health had an incredible year of growth holding 60% chemotherapy compounding market share in Australia and producing over 1.5 million infusions annually.2023 saw the opening of a new TGA licensed facility in Woodville, South Australia marking Slade’s fifth compounding facility and continuing a proven track record of delivering quality products to hospitals across Australia. The Slade Health Avondale facility in Auckland and the Research Stability Lab in Mt Kuring-gai, Sydney celebrated one year of operations with notable improvements to the extending the shelf-life of compounded medications allowing greater accessibility to life-saving drugs. - Best in class pharmacy management
Icon’s national pharmacy network grew from strength to strength with a significant contract win for Slade Pharmacy who will provide pharmacy services for UnitingCare Queensland hospitals. - Connecting with our communities
Continuing a strong track-record in industry partnerships Icon hosted regional forums in Townsville and Maitland, attended by local patient advocacy groups, to help address gaps in the cancer care experience and take meaningful actions to improving patient navigation.
Future healthcare
- Introduction of theranostics
October saw the launch of Icon’s theranostics program at Icon Cancer Centre North Lakes in Brisbane’s north. This marks a major advancement in our comprehensive cancer treatment services and highlights our continued commitment to advancing cancer care. The oncology market for theranostics is expected to grow to more than $129 billion by 2025, providing a significant pipeline of industry funded clinical trial which will see Icon continue to broaden our clinical trials network and capability. - Nurturing industry partnerships
Through our long-term global partnership with industry leaders, Varian Medical Systems, Icon continued to introduce first to market technology to our cancer care network including Varian’s HyperSight technology.
Delivering on a global mission
Icon Group CEO, Mark Middleton says the team’s achievements marked a significant step towards achieving Icon’s mission to bring the best care possible to more people closer to home.
“We’ve had an incredible year of delivering care to more people and remain a leading values-led cancer care organisation united by a common goal to make a difference,” said Mark.
“We have a strong growth pipeline with a strategic and considered plan to continue investing in regions where we can sustainably introduce new services and Icon’s proven model of comprehensive care.
“We’re delivering truly world-class services and care that feels like home, providing confidence and hope to people at their most vulnerable time, and the Icon team will continue turning the dial on cancer care in 2024 and beyond.”
A career with Icon
At Icon, you’ll help change lives, every single day. In return for your passion, dedication and agility, we offer a workplace where you can.
Fifth Icon Cancer Centre opens in China
Read more about our latest radiation oncology service in Mainland China
Icon Cancer Centre
Learn more about our cancer centre network in Australia
Updates
Read the latest news and updates across Icon Group